vs
Alkermes plc.（ALKS）与COMPASS MINERALS INTERNATIONAL INC（CMP）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是Alkermes plc.的1.0倍（$396.1M vs $384.5M），Alkermes plc.净利率更高（12.8% vs 4.7%，领先8.1%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $-59.8M），过去两年Alkermes plc.的营收复合增速更高（4.8% vs 4.3%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
ALKS vs CMP — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $396.1M |
| 净利润 | $49.3M | $18.6M |
| 毛利率 | 88.0% | 16.0% |
| 营业利润率 | 15.1% | 9.2% |
| 净利率 | 12.8% | 4.7% |
| 营收同比 | -10.6% | 28.9% |
| 净利润同比 | -66.3% | 178.8% |
| 每股收益（稀释后） | $0.29 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $384.5M | $396.1M | ||
| Q3 25 | $394.2M | $227.5M | ||
| Q2 25 | $390.7M | $214.6M | ||
| Q1 25 | $306.5M | $494.6M | ||
| Q4 24 | $430.0M | $307.2M | ||
| Q3 24 | $378.1M | $208.8M | ||
| Q2 24 | $399.1M | $202.9M | ||
| Q1 24 | $350.4M | $364.0M |
| Q4 25 | $49.3M | $18.6M | ||
| Q3 25 | $82.8M | $-7.2M | ||
| Q2 25 | $87.1M | $-17.0M | ||
| Q1 25 | $22.5M | $-32.0M | ||
| Q4 24 | $146.5M | $-23.6M | ||
| Q3 24 | $92.4M | $-48.3M | ||
| Q2 24 | $91.4M | $-43.6M | ||
| Q1 24 | $36.8M | $-38.9M |
| Q4 25 | 88.0% | 16.0% | ||
| Q3 25 | 86.9% | 16.9% | ||
| Q2 25 | 87.3% | 19.2% | ||
| Q1 25 | 83.9% | 15.5% | ||
| Q4 24 | 85.6% | 11.2% | ||
| Q3 24 | 83.3% | 9.3% | ||
| Q2 24 | 84.6% | 16.1% | ||
| Q1 24 | 83.3% | 19.7% |
| Q4 25 | 15.1% | 9.2% | ||
| Q3 25 | 22.6% | 5.3% | ||
| Q2 25 | 23.8% | 7.4% | ||
| Q1 25 | 4.5% | -0.6% | ||
| Q4 24 | 37.8% | 0.2% | ||
| Q3 24 | 27.7% | -14.3% | ||
| Q2 24 | 27.5% | 2.9% | ||
| Q1 24 | 12.4% | -10.8% |
| Q4 25 | 12.8% | 4.7% | ||
| Q3 25 | 21.0% | -3.2% | ||
| Q2 25 | 22.3% | -7.9% | ||
| Q1 25 | 7.3% | -6.5% | ||
| Q4 24 | 34.1% | -7.7% | ||
| Q3 24 | 24.4% | -23.1% | ||
| Q2 24 | 22.9% | -21.5% | ||
| Q1 24 | 10.5% | -10.7% |
| Q4 25 | $0.29 | $0.43 | ||
| Q3 25 | $0.49 | — | ||
| Q2 25 | $0.52 | $-0.41 | ||
| Q1 25 | $0.13 | $-0.77 | ||
| Q4 24 | $0.88 | $-0.57 | ||
| Q3 24 | $0.55 | $-1.17 | ||
| Q2 24 | $0.53 | $-1.05 | ||
| Q1 24 | $0.21 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $46.7M |
| 总债务越低越好 | — | $890.0M |
| 股东权益账面价值 | $1.8B | $260.5M |
| 总资产 | $2.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 3.42× |
8季度趋势，按日历期对齐
| Q4 25 | $388.6M | $46.7M | ||
| Q3 25 | $616.4M | $59.7M | ||
| Q2 25 | $521.2M | $79.4M | ||
| Q1 25 | $399.8M | $49.5M | ||
| Q4 24 | $291.1M | $45.8M | ||
| Q3 24 | $396.3M | $20.2M | ||
| Q2 24 | $535.1M | $12.8M | ||
| Q1 24 | $420.8M | $38.3M |
| Q4 25 | — | $890.0M | ||
| Q3 25 | — | $839.8M | ||
| Q2 25 | — | $833.4M | ||
| Q1 25 | — | $807.6M | ||
| Q4 24 | — | $974.4M | ||
| Q3 24 | — | $921.2M | ||
| Q2 24 | — | $875.1M | ||
| Q1 24 | — | $877.2M |
| Q4 25 | $1.8B | $260.5M | ||
| Q3 25 | $1.7B | $234.1M | ||
| Q2 25 | $1.6B | $249.8M | ||
| Q1 25 | $1.5B | $236.5M | ||
| Q4 24 | $1.5B | $263.0M | ||
| Q3 24 | $1.3B | $316.6M | ||
| Q2 24 | $1.3B | $352.1M | ||
| Q1 24 | $1.3B | $400.4M |
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.3B | $1.5B | ||
| Q2 25 | $2.3B | $1.5B | ||
| Q1 25 | $2.1B | $1.5B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.2B | $1.6B | ||
| Q2 24 | $2.2B | $1.6B | ||
| Q1 24 | $2.1B | $1.7B |
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | 3.41× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 2.49× | ||
| Q1 24 | — | 2.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $-37.0M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $-59.8M |
| 自由现金流率自由现金流/营收 | 44.2% | -15.1% |
| 资本支出强度资本支出/营收 | 0.0% | 5.8% |
| 现金转化率经营现金流/净利润 | 3.45× | -1.99× |
| 过去12个月自由现金流最近4个季度 | $480.3M | $94.1M |
8季度趋势，按日历期对齐
| Q4 25 | $170.1M | $-37.0M | ||
| Q3 25 | $101.7M | $-6.9M | ||
| Q2 25 | $150.2M | $21.8M | ||
| Q1 25 | $98.8M | $186.9M | ||
| Q4 24 | $190.4M | $-4.1M | ||
| Q3 24 | $81.6M | $-12.7M | ||
| Q2 24 | $146.0M | $-6.8M | ||
| Q1 24 | $21.1M | $86.2M |
| Q4 25 | $170.0M | $-59.8M | ||
| Q3 25 | $84.4M | $-22.8M | ||
| Q2 25 | $137.2M | $3.8M | ||
| Q1 25 | $88.7M | $172.9M | ||
| Q4 24 | $180.6M | $-25.9M | ||
| Q3 24 | $73.3M | $-33.6M | ||
| Q2 24 | $138.9M | $-21.5M | ||
| Q1 24 | $12.8M | $56.2M |
| Q4 25 | 44.2% | -15.1% | ||
| Q3 25 | 21.4% | -10.0% | ||
| Q2 25 | 35.1% | 1.8% | ||
| Q1 25 | 28.9% | 35.0% | ||
| Q4 24 | 42.0% | -8.4% | ||
| Q3 24 | 19.4% | -16.1% | ||
| Q2 24 | 34.8% | -10.6% | ||
| Q1 24 | 3.6% | 15.4% |
| Q4 25 | 0.0% | 5.8% | ||
| Q3 25 | 4.4% | 7.0% | ||
| Q2 25 | 3.3% | 8.4% | ||
| Q1 25 | 3.3% | 2.8% | ||
| Q4 24 | 2.3% | 7.1% | ||
| Q3 24 | 2.2% | 10.0% | ||
| Q2 24 | 1.8% | 7.2% | ||
| Q1 24 | 2.4% | 8.2% |
| Q4 25 | 3.45× | -1.99× | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
